Banu Arun, MD, of The University of Texas MD Anderson Cancer Center, discusses a session she moderated that included discussion of how exercise and diet may reduce the risk of breast cancer, and emerging non-endocrine treatments that may help prevent the disease.
Javier Cortés, MD, PhD, of the International Breast Cancer Center, discusses the final phase III results of KEYNOTE-355, which showed that pembrolizumab and chemotherapy improved overall and progression-free survival, compared with placebo and chemotherapy, for patients with previously untreated, locally recurrent, inoperable or metastatic triple-negative breast cancer (Abstract GS1-02 ).
Patricia A. Ganz, MD, of the University of California, Los Angeles, discusses quality-of-life results from the phase III OlympiA study of adjuvant olaparib after (neo)adjuvant chemotherapy in patients with germline BRCA1/2 mutations and high-risk HER2-negative early breast cancer (Abstract GS4-09).
François-Clément Bidard, MD, PhD, of the Institut Curie, discusses phase III findings of the PADA-1 study, which showed that optimizing endocrine therapy after detecting the ESR1 mutation in patients with hormone receptor–positive, HER2-negative metastatic breast cancer may double their median progression-free survival (Abstract GS3-05).
Peter Schmid, MD, PhD, of Barts Cancer Institute, discusses phase III findings from KEYNOTE-522, in which researchers found a generally consistent event-free survival benefit among patients with early-stage high-risk triple-negative breast cancer who were treated with neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab (Abstract GS1-01).
Elizabeth A. Mittendorf, MD, PhD, of Dana-Farber Brigham and Women’s Cancer Center, discusses the progress made in recent years treating patients with triple-negative breast cancer (TNBC), including approval of the immunotherapy agents pembrolizumab and sacituzumab govitecan-hziy, a new standard of care in the preoperative setting for early-stage disease, as well as a better understanding of the biology of TNBC and its heterogeneity.
